Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic

被引：0
|
作者：
Cutler, Andrew J. [1 ]
Edwards, John B. [2 ]
Durgam, Suresh [2 ]
Mo, Yifan [2 ]
Acosta, Jazmin [2 ]
Davis, Robert E. [2 ]
机构：
[1] SUNY Upstate Med Univ, Dept Psychiat, Lakewood Ranch, FL USA
[2] Intra Cellular Therapies Inc, New York, NY USA
来源：
CNS SPECTRUMS | 2023年 / 28卷 / 02期
关键词：
D O I：
10.1017/S1092852923001645
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [1] Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
    Correll, Christoph U.
    Vanover, Kimberly E.
    Davis, Robert E.
    Chen, Richard
    Satlin, Andrew
    Mates, Sharon
    SCHIZOPHRENIA RESEARCH, 2021, 228 : 198 - 205
  • [2] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
    Correll, C. U.
    Vanover, K. E.
    Durgam, S.
    Weingart, M.
    Davis, R.
    Satlin, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456
  • [3] Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia
    Satlin, Andrew
    Vanover, Kimberly
    Durgam, Suresh
    Mates, Sharon
    Davis, Robert
    Correll, Christoph
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 493 - 494
  • [4] Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan
    Ishigooka, J
    Murasaki, M
    Miura, S
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 55 (04) : 353 - 363
  • [5] Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study
    Apiquian, R
    Ulloa, E
    Fresan, A
    Loyzaga, C
    Nicolini, H
    Kapur, S
    SCHIZOPHRENIA RESEARCH, 2003, 59 (01) : 35 - 39
  • [6] Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study
    Lindenmayer, JP
    Czobor, P
    Volavka, J
    Lieberman, JA
    Citrome, L
    Sheitman, B
    Chakos, M
    McEvoy, JP
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) : 931 - 935
  • [7] Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
    Yang, Fu De
    Li, Juan
    Tan, Yun Long
    Liang, Wei Ye
    Zhang, Rongzhen
    Wang, Ning
    Feng, Wei
    Cai, Shangli
    Zhuo, Jian Min
    Zhang, Li Li
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1089 - 1097
  • [8] Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
    Miura, Itaru
    Watabe, Kei
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Maruyama, Hidenori
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2627 - 2637
  • [9] FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA
    Vanover, Kimberly
    Satlin, Andrew
    Durgam, Saresh
    Weingart, Michal
    Saillard, Jelena
    Sanchez, Juan
    Hossain, Shawon
    Glass, Steven
    Kozauer, Susan
    Mates, Sharon
    Davis, Robert
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S351 - S351
  • [10] Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: A pilot open-label trial
    Lerner, Vladimir
    Miodownik, Chanoch
    Gibel, Anatoly
    Kovalyonok, Ekateryna
    Shleifer, Tatyana
    Goodman, Ann B.
    Ritsner, Michael S.
    CLINICAL NEUROPHARMACOLOGY, 2008, 31 (01) : 25 - 33
12345